Obsessive-Compulsive Disorder Drugs Market to grow with a CAGR of 7.60%
Increasing
healthcare infrastructure and a supportive regulatory environment are the major
drivers for the Global Obsessive-Compulsive Disorder Drugs Market.
According
to TechSci Research report, “Global Obsessive-Compulsive Disorder Drugs Market
Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Obsessive-Compulsive
Disorder Drugs Market has valued at USD 882.50 million in 2022 and is
anticipated to witness an impressive growth in the forecast period with a CAGR
of 7.60% through 2028. This can be due to collaborations and partnerships among
leading companies with a diverse approach to merge the expertise of individual
companies and to strengthen their position in the market.
Research
into the neurobiology of obsessive-compulsive disorder (OCD) is a significant
driver for the Global OCD Drugs Market. Understanding the underlying
neurobiological mechanisms of OCD is crucial for the development of more
effective medications and treatment strategies. Neurobiological research helps
identify specific neurochemical pathways and brain regions involved in the
development and manifestation of OCD symptoms. This knowledge provides
pharmaceutical companies with potential drug targets to develop new medications
that can modulate these pathways. Insights from neurobiology research can lead
to the development of more targeted therapies. By understanding the neural
circuits and neurotransmitter systems involved in OCD, researchers can design
drugs that specifically address the underlying causes of the disorder,
potentially making them more effective than current treatments. Neurobiological
insights may support the development of combination therapies that target
multiple aspects of OCD's neurobiology. These combinations can include both
pharmacological and non-pharmacological interventions, potentially improving
treatment outcomes.
Obsessive-Compulsive
Disorder (OCD) is a mental health disorder characterized by the presence of
obsessions and compulsions that significantly interfere with a person's daily
life and well-being. It is considered an anxiety disorder because it often
involves persistent, intrusive thoughts (obsessions) and repetitive behaviors
or mental acts (compulsions) aimed at reducing the distress caused by these
obsessions. OCD is treatable, and there are several effective treatment
approaches, including psychotherapy (particularly Cognitive-Behavioral Therapy
with Exposure and Response Prevention, or CBT-ERP) and medications (such as
Selective Serotonin Reuptake Inhibitors, or SSRIs). A combination of therapy
and medication is often recommended for severe cases.
In
June 2022, Brexpiprazole's phase III clinical trial for the management of
agitation in patients with Alzheimer's dementia (NCT03548584) has shown
encouraging findings, according to Otsuka Pharmaceutical Co., Ltd. (Otsuka) and
H. Lundbeck A/S (Lundbeck). The investigation found that there is a
statistically significant difference between brexpiprazole and placebo in the
mean change in the Cohen-Mansfield Agitation Inventory (CMAI) total score from
baseline to week 12 (p=0.0026). The goal of Trial 331-14-213 (NCT03548584;
Trial 213) was to evaluate the effectiveness of two fixed doses of
brexpiprazole in the treatment of individuals with agitation associated with
Alzheimer's disease. The two dosages were 2 mg/day or 3 mg/day. Patients taking
brexpiprazole at doses of 2 mg or 3 mg per day or placebo experienced
significantly higher improvements from baseline on the study's primary goal of
CMAI (p=0.0026).
The
limited efficacy of current treatments is a challenge for the Global
Obsessive-Compulsive Disorder (OCD) Drugs Market. While there are various
treatment options available for OCD, not all individuals respond equally to
these treatments, and a significant proportion of patients may experience only
partial relief or no improvement in symptoms. For a substantial number of
individuals with OCD, currently available treatments, including medication and
psychotherapy, may not adequately alleviate their symptoms. This leaves a
significant unmet medical need for more effective treatments. Many current OCD
medications are associated with side effects that can be intolerable for some
patients. This can lead to treatment discontinuation, reducing the overall
effectiveness of available treatments. Not all individuals with OCD respond to
medications or psychotherapy in the same way. The variability in treatment
response means that there is no one-size-fits-all solution, and alternative
treatment options are needed.
Browse over XX market data Figures and spread through 110 Pages and an
in-depth TOC on "Global Obsessive-Compulsive Disorder Drugs Market.”
Global Obsessive-Compulsive Disorder Drugs Market segmentation
is based on
Type, Application and Region.
Based on Type, Global Obsessive-Compulsive Disorder Drugs Market is segmented
into SSRI (Selective Serotonin Reuptake Inhibitors), TCA (Tricyclic
Antidepressant). Tricyclic
Antidepressants (TCAs) are a class of prescription medications primarily used
for the treatment of various mental health conditions, with a focus on
depression. They were one of the first types of antidepressants developed and
have been in use since the 1950s. While newer antidepressant classes, such as
Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine
Reuptake Inhibitors (SNRIs), have become more common, TCAs are still prescribed
in certain cases when other treatments are ineffective or when their specific
effects are desired. TCAs work
by increasing the levels of certain neurotransmitters (chemical messengers) in
the brain, namely serotonin and norepinephrine. By inhibiting the reuptake of
these neurotransmitters, TCAs allow them to remain in the synaptic gap between
nerve cells, which can lead to improved mood and reduced symptoms of
depression.
Based on Region, North America dominated the Global Obsessive-Compulsive
Disorder Drugs Market. North America has a robust network of patient
advocacy and support groups dedicated to OCD and related mental health
disorders. These organizations raise awareness, provide resources, and advocate
for improved access to treatment, further contributing to the prominence of OCD
in the region. Pharmaceutical companies in North America have well-established
marketing and sales strategies, which can influence the prescription patterns
of healthcare providers and promote the use of OCD medications. Over the years,
there has been an increased focus on mental health awareness and
destigmatization of mental disorders in North America. This has led to more
individuals seeking help and being diagnosed with conditions like OCD, thereby
driving demand for treatment. In the United States, health insurance coverage
is widespread, which helps patients access necessary medications, including
those for OCD, more easily. Insurance coverage can significantly reduce the
out-of-pocket costs for patients.
Asia-pacific region to fastest growth in
the Global Obsessive-Compulsive Disorder Drugs Market. There has been a notable
shift in recent years towards increased mental health awareness in many APAC
countries. Advocacy campaigns, government initiatives, and the work of mental
health organizations have helped reduce stigma, encouraging individuals to seek
help for conditions like OCD. As APAC countries industrialize and urbanize,
there has been a reported increase in the prevalence of mental health
conditions, including OCD. This higher prevalence has driven greater demand for
OCD drugs and mental health services. Rapid economic growth in some APAC
countries has led to an increase in the middle-class population. This
demographic tends to have better access to healthcare services, including
mental health treatment, and is more likely to seek treatment for mental health
conditions.
Some
of the major companies operating in the Global
Obsessive-Compulsive Disorder Drugs Market include:
- Abbott
SA
- Eli
Lilly, and Company
- Viatria
Inc.
- H.
LUNDBECK A/S,
- GlaxoSmithKline
plc
- Pfizer
Inc.
- Zydus
Pharmaceuticals, Inc.
- Lupin
Pharmaceuticals, Inc.
- Amneal
Pharmaceuticals LLC
- Teva
Pharmaceutical industries Ltd.
Download Free Sample Report
Customers can also request
10% free customization on this report.
“Certain areas, particularly in
North America, are projected to exert significant demand for OCD Drugs. The
growth in the competitive landscape and the presence of well-established
companies in the market, committed to enhance the overall wellbeing of people each
year, are expected to contribute to a remarkable growth of the Global Obsessive-Compulsive
Disorder Drugs Market in the forecast period," said Mr. Karan Chechi,
Research Director with TechSci Research, a research-based Global management
consulting firm.
Obsessive-Compulsive
Disorder Drugs Market – Global Industry Size, Share, Trends, Opportunity, and
Forecast, 2018-2028 Segmented by Type (SSRI (Selective Serotonin Reuptake
Inhibitors), TCA (Tricyclic Antidepressant)), by Application (Research
Institute, Hospitals & Clinics, Others), by region, and Competition evaluated
the future growth potential of Global Obsessive-Compulsive Disorder Drugs Market
and provides statistics & information on market size, structure, and future
market growth. The report intends to provide innovative market intelligence and
help decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Obsessive-Compulsive Disorder Drugs Market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York 10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com